Log in to search using one of your social media accounts:

 

Reyataz (Atazanavir Sulfate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Updates Atazanavir Oral Powder Label
"On September 24, 2015, FDA approved revisions to the Reyataz (atazanavir) oral powder label to include dosing recommendations for patients three months and older weighing at least 5 kg. This represents the addition of a new pediatric weight band. Previously the oral powder formulation was for patients three months and older weighing at least 10 kg.   "Reyataz oral powder must be taken with ritonavir and is not recommended for use in children who weigh less than 5 kg."   The updated labeling will be available at the FDA website.   More information is available: FDA: Press release AIDSinfo...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 9, 2015 Category: Infectious Diseases Source Type: news

View AIDSinfo Patient Fact Sheets on Three Recently Approved HIV Medications
AIDSinfo invites you to view our patient fact sheets on three medications recently approved by the FDA. The three medications are all indicated for use in the treatment of HIV infection in adults. The patient fact sheets include information on dosage forms and strengths, possible side effects, and instructions on how to take and store the medications. Fact sheet on abacavir/dolutegravir/lamivudine (brand name: Triumeq) Triumeq is a combination medicine that can be used alone as a complete treatment regimen or with other HIV medicines. Fact sheet on cobicistat (brand name: Tybost) Cobicistat is a pharmacoki...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 24, 2014 Category: Infectious Diseases Source Type: news

New Pediatric Dosage Form and Label Changes for Reyataz (Atazanavir)
"On June 2, 2014, FDA approved a new dosage form, Reyataz (atazanavir) oral powder for use in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10 kg to
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 20, 2014 Category: Infectious Diseases Source Type: news

BMS Files Reyataz-Cobicistat Combo Tablet NDA For HIV-1
Bristol-Myers Squibb announced the filing of a New Drug Application for the fixed-dose combination tablet of atazanavir sulfate (marketed under the brand name Reyataz) with cobicistat for the treatment of patients with HIV-1. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 15, 2014 Category: Pharmaceuticals Source Type: news

FDA Updates Atazanavir Sulfate Capsule Labeling
“Recently [February 4, 2013] FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes. “Section 5 Warnings and Precautions was revised to include cholelithiasis ...   “In section 6 Adverse Reactions: Postmarketing Experience, interstitial nephritis was added. “In section 7 Drug Interactions: information regarding coadministration with boceprevir, carbamazepine, phenytoin, phenobarbital, lamotrigine and voriconazole was added.” The updated labeling will be available at the FDA website. More information is available: FDA: Press releas...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 12, 2013 Category: Infectious Diseases Source Type: news